Hutch News
Breaking down HIV exclusions in cancer clinical trials
As an eligibility barrier cracks, a lung cancer patient gets a new lease on life
Increased racial and ethnic minority participation in HIV vaccine trials
From the HIV Vaccine Trials Network, Vaccine and Infectious Disease Division
Structural and clinical barriers keep 3 of 4 cancer patients from participating in trials
‘Patients are willing to participate in trials if they’re offered one’
Comorbidities impede clinical trial participation
From the Unger Group, Public Health Sciences Division
How to boost cancer clinical trial participation
New study suggests loosening strict comorbidity criteria would open trials to thousands of previously exempt patients
“Exciting” but early results in trial of immunotherapy for myeloma
Cancer cells disappeared rapidly in patients with high-risk, treatment-resistant disease
Revealing a new way that cancer can evade immunotherapy — and, maybe, how to stop it
How a new technology solved a mystery and honors one man’s legacy
UCI-Fred Hutch collaboration turns 10
In Uganda, innovation and persistence allow a 'sustainable cancer program' to take root
Fred Hutch at ASCO
Immunotherapy advances, insights into health economics and leadership awards dominate oncology gathering
What's new in prostate cancer: 5 takeaways
‘Many reasons for optimism’ says expert at annual community symposium
Early phase clinical trial shows promise for advanced head and neck cancer
Nine out of 10 patients treated with the experimental therapy saw their tumors shrink
With approval of new CMV drug for transplant patients, a legacy continues
Tissue samples from a clinical trial conducted decades ago yield new insights and treatments
Meet Global Oncology's deputy program head
Key early experiences shaped Dr. Thomas Uldrick's path toward HIV-associated cancers, global health
How new drugs become available to more patients
Filling in the unknowns on the balance between risk and benefit
New insights into CAR T-cell therapy's potential side effects
<p>Detailed study of cytokine release syndrome and neurologic toxicities could help make emerging cancer immunotherapies safer</p>
For cancer patients with HIV, immunotherapy appears safe
Checkpoint inhibitor study suggests new treatment options for patients long excluded from cancer immunotherapy clinical trials
One family, two sides of cancer
Basic scientist Dr. Wenying Shou’s parents were both treated for — and cured of — their cancers. The similarities end there.
Teacher, mom — and living immunotherapy proof of principle
Three years ago she was out of options to treat her advanced cancer. Then, she enrolled in an immunotherapy clinical trial.
Why volunteer for an HIV cure study?
Why volunteer for an HIV cure study? A community group undertakes its own research to find out
Experimental herpes drug pritelivir more effective than standard treatment
Pritelivir reduces viral shedding and lesions better than valacyclovir, study shows
Community is key for new, large HIV vaccine trial
Community trust is key as researchers start a new trial across 15 sites in South Africa
Empowering ‘millions of women’ against HIV
AMP study in sub-Saharan Africa tests an antibody infusion that could put protection in women’s hands
New approach aims to restore immune-powering B cells in cancer patients following successful immunotherapy with CAR T cells
New approach, not yet tested in humans, aims to restore immune-powering B cells in cancer patients following successful CAR T-cell therapy